Printer Friendly

BIOPOOL SIGNS LETTER OF INTENT FOR $2 MILLION FINANCING

 VENTURA, Calif., March 17 /PRNewswire/ -- Biopool International Inc. (NASDAQ: BIPL) today announced it has signed a letter of intent to sell $2 million of its unregistered common stock to International Capital Partners Inc., a Stamford, Conn.-based investment company that specializes in providing capital and advisory services to smaller-growth companies. The financing is expected to be completed by April 30, 1993.
 "The proceeds from the private placement will be used to pay down existing debt, for capital equipment and expenditures, to increase research and development, and to promote marketing efforts, thereby enhancing our continuing growth strategy," said Michael D. Bick, Ph.D., chief executive officer.
 Founded in 1987, Biopool develops, manufactures and markets a full range of test kits to assess and diagnose disorders of blood coagulation, fibrinolysis, platelet function and the vascular system, as well as test kits to determine thrombotic risk factors. The company's products are sold to hospitals and clinical laboratories worldwide.
 -0- 3/17/93
 /CONTACT: Michael D. Bick, Ph.D., CEO, 805-654-0643, or Andrew L. Cerskus (Canada), Ph.D., president, 416-332-9419, both of Biopool; or Kim P. Feazle or Roger S. Pondel of Pondel Parsons & Wilkinson, 310-207-9300, for Biopool/
 (BIPL)


CO: Biopool International Inc. ST: California IN: MTC SU:

BP-KJ -- LA004 -- 6900 03/17/93 09:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1993
Words:213
Previous Article:YELLOW CORPORATION IS PROPOSED NAME
Next Article:NEXT GENERATION OF SCIENTISTS USES SUPERCOMPUTER FROM THINKING MACHINES; BOSTON UNIVERSITY PROVIDES MASSIVELY PARALLEL COMPUTING TO UNDERGRADS
Topics:


Related Articles
BIOPOOL INTERNATIONAL INC. COMPLETES THE ACQUISITION OF MEDICAL DIAGNOSTIC TECHNOLOGIES INC.
BIOPOOL REPORTS FIRST QUARTER RESULTS AND FIFTH CONSECUTIVE PROFITABLE QUARTER
BIOPOOL COMPLETES FINANCING
BIOPOOL POSTS SECOND QUARTER OPERATING RESULTS
BIOPOOL RECEIVES FDA APPROVAL FOR THERAPEUTIC DRUG MONITORING CONTROL
BIOPOOL INTERNATIONAL RECEIVES FDA APPROVAL TO MARKET FIVE (5) NEW CHEMISTRY REAGENT SYSTEMS
I-FLOW CORPORATION ANNOUNCES STRATEGIC ACQUISITION AGREEMENT
BIOPOOL/XTRANA REPORTS 11% SALES INCREASE AND NET LOSS.
BUSINESS NOTES\Developments.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters